Loading clinical trials...

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis

Clinical Trial Evaluating the Efficacy of Homologous Allogeneic Hepatocytes in Patients With Decompensated Cirrhosis

NCT06306781•RenJi Hospital

View on ClinicalTrials.gov

Summary

This study protocol is designed to evaluate the clinical efficacy, safety, and tolerability of HCL001 cell injection in the treatment of decompensated cirrhosis. The aim is to provide stronger evidence for the clinical application of HCL001 cell injection in the treatment of decompensated cirrhosis, thereby attempting to improve patients' survival and quality of life to meet the clinical needs for treating decompensated liver cirrhosis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•When signing the informed consent form, individuals between the ages of 18 to 75 years (inclusive, including the boundary values) are eligible, and there are no restrictions based on gender.
•According to the "Guidelines for the Diagnosis and Treatment of Cirrhosis (2019 Edition)", a diagnosis of decompensated cirrhosis is made.
•A Child-Pugh score of 7-12 points (including the threshold) is classified as \[insert the corresponding classification as per the provided appendix\].
•An ECOG performance status score of 0-2 or a Karnofsky Performance Status (KPS) score greater than 60 is considered \[insert the corresponding classification or interpretation\].
•A safe vascular access that allows for hepatic intra-arterial catheterization and angiography
•If screening for patients with hepatitis B or C-related cirrhosis, the viral load should be ≤1000 IU/mL for HBV-DNA and ≤15 IU/mL for HCV-RNA. For patients with alcoholic cirrhosis, the abstinence period should be ≥6 months.
•During screening, the serum ALT level should be ≤3 times the upper limit of normal (ULN).
•Understand and adhere to the research process, voluntarily participate, and sign the informed consent form (the informed consent form is to be voluntarily signed by myself or a legally authorized representative).

Exclusion Criteria

•Allergic individuals, especially those allergic to any component of HCL001 cell injection or its excipients.
•Individuals with concurrent liver cancer or other malignant tumors.
•Patients who are unable or unwilling to cooperate or comply with the requirements of the research protocol.
•International Normalized Ratio (INR) \>2.5 and platelet count (PLT) less than 30 x 10\^9/L.
•Patients who have used anticoagulant or antiplatelet medications within the past week prior to screening.
•Patients with a history of upper gastrointestinal bleeding or spontaneous peritonitis within the past four weeks prior to screening.
•Patients who have experienced grade 3 or higher hepatic encephalopathy within the past three months prior to administering the medication.
•Patients with severe dysfunction in vital organs such as the heart, lungs, brain, or kidneys, including: History of severe lung diseases such as severe emphysema, pulmonary embolism, or other lung conditions that significantly impact lung function. Significant history of heart disease that meets either of the following conditions: a. Decompensated heart failure (New York Heart Association \[NYHA\] class III-IV). b. Unstable angina. Chronic kidney disease, such as chronic nephritis, renal insufficiency, or uremia.
•For patients with diabetes mellitus that is being treated but not effectively controlled, it typically refers to those with a glycated hemoglobin (HbA1c) level of ≥8%.
•Patients with severe coagulation dysfunction or bleeding disorders, such as hemophilia, as well as those with severe jaundice indicated by a serum total bilirubin level of ≥171 μmol/L.
+5 more criteria

Key Dates

Start Date

March 30, 2024

Primary Completion Date

July 30, 2026

Completion Date

December 30, 2026

Last Updated

March 12, 2024

Enrollment

ESTIMATED participants

Conditions

Decompensated Cirrhosis

Interventions

HCL001 cell (homologous allogeneic hepatocytes) injection

DRUG

Contacts

Qiang Xia, Professor

CONTACT

13661889035 xiaqiang@medmail.com

Han-yong Sun, Doctor

CONTACT

15921197267 hanyongsun@163.com

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

NCT06855056

Liver CirrhosisDecompensated Cirrhosis of Liver

View study

RECRUITINGNA

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

NCT06431919

Decompensated CirrhosisCirrhotic Cardiomyopathy+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis

Inclusion Criteria

Exclusion Criteria

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Incidence & Predictive Factors of Recompensation in Children With Decompensated Cirrhosis as Per the Baveno VII Criteria

Primary Prophylaxis for Spontaneous Bacterial Peritonitis

CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis